Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human dose-escalation study of [225Ac]-AZD2284 in metastatic castration-resistant prostate cancer
PACTR202607505608191Phase 1Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2025
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in prostate cancer (PCa), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of AZD2284, AZD2287, and AZD2275 and Recommended Phase 2 dose of AZD2284. Planned start Jan 2025; status: not yet recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on PACTR202607505608191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202607505608191.